Nisa Investment Advisors LLC Has $5.53 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Nisa Investment Advisors LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 47.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,133 shares of the biopharmaceutical company’s stock after buying an additional 3,891 shares during the period. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $5,533,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $243,000. Geneos Wealth Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the period. Strs Ohio bought a new position in Alnylam Pharmaceuticals during the first quarter worth $7,781,000. Swedbank AB lifted its holdings in Alnylam Pharmaceuticals by 8.0% in the first quarter. Swedbank AB now owns 59,993 shares of the biopharmaceutical company’s stock valued at $16,199,000 after buying an additional 4,461 shares during the period. Finally, AG2R LA Mondiale Gestion D Actifs acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at $1,573,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $398.29 on Monday. The company has a market cap of $52.62 billion, a PE ratio of 1,659.54 and a beta of 0.32. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock has a 50-day moving average price of $425.72 and a 200-day moving average price of $421.24. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the sale, the chief executive officer directly owned 65,409 shares in the company, valued at $29,517,119.43. The trade was a 13.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 37,778 shares of company stock worth $17,096,988 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ALNY. Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research report on Monday, October 6th. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Jefferies Financial Group dropped their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. HC Wainwright set a $570.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Leerink Partners decreased their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $484.21.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.